Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers. The investigational mRNA cancer immunotherapy is ...

An experimental mRNA cancer vaccine shows promising results in a Phase 1 trial, potentially offering new hope for ...

Vaccines are safe and effective, but we're up against this polarization right now. It's difficult, it's hard to do the work,' ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

I am deeply troubled by the growing distrust of science in our society, just at the time when its insights are most needed.

alternative 3′, alternative 5′, and intron retention); the spliceosome complex and various regulatory proteins encompass the pre-mRNA and excise the individual introns; and examples of mRNA before and ...

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients ...

The mRNA immunotherapy is just one of many cancer ... The results should be treated with caution, say the study authors, as the sample size was small and the primary objective of the study was ...